Display options
Share it on

Hepat Med. 2010 Feb 23;2:33-8. doi: 10.2147/hmer.s7187.

Mechanism of the inhibitory effect of ghrelin in sepsis.

Hepatic medicine : evidence and research

Asha Jacob, Rongqian Wu, Mian Zhou, Gene F Coppa, Ping Wang

Affiliations

  1. Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, and The Feinstein Institute for Medical Research, Manhasset, NY, USA.

PMID: 24367207 PMCID: PMC3846870 DOI: 10.2147/hmer.s7187

Abstract

Sepsis and septic shock are the leading causes of death in intensive care units. Approximately 40%-70% of the mortality is associated with severe sepsis and septic shock. Systemic antibiotic usage, surgical intervention, aggressive fluid resuscitation and careful monitoring are common measures currently used to treat sepsis. Despite the advances in the understanding of the pathophysiology of sepsis, very little progress has been made towards therapeutic interventions. Recently we have shown that ghrelin, a stomach-derived peptide which is an endogenous ligand for the growth hormone secretagogue receptor (GHSR-1a), is beneficial in attenuating the inflammatory response, organ injury and mortality in an experimental model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). In this review, we describe the mechanism of action of ghrelin in sepsis, highlight the role ghrelin plays in attenuating the hepatic dysfunction induced by sepsis and septic shock and suggest in developing ghrelin as a potential therapy for sepsis.

Keywords: GHSR-1a; cecal ligation; ghrelin; inhibition septic shock; sepsis

References

  1. Ann Surg. 2009 Jul;250(1):126-33 - PubMed
  2. Biochem Biophys Res Commun. 2000 Aug 28;275(2):477-80 - PubMed
  3. PLoS One. 2009;4(5):e5504 - PubMed
  4. Ann Surg. 2007 Mar;245(3):480-6 - PubMed
  5. Endocrinol Metab Clin North Am. 2007 Mar;36(1):233-45 - PubMed
  6. Int J Mol Med. 2010 Jan;25(1):159-64 - PubMed
  7. J Neuroendocrinol. 2000 Dec;12(12):1194-9 - PubMed
  8. Am J Physiol. 1996 May;270(5 Pt 2):R927-38 - PubMed
  9. Endocrinology. 2004 Jun;145(6):2604-6 - PubMed
  10. Crit Care Med. 2001 Jul;29(7):1303-10 - PubMed
  11. Biochim Biophys Acta. 2001 Jul 27;1537(1):49-57 - PubMed
  12. Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1274-81 - PubMed
  13. Nature. 1999 Dec 9;402(6762):656-60 - PubMed
  14. Circ Shock. 1987;22(4):281-90 - PubMed
  15. Shock. 1995 Oct;4(4):269-73 - PubMed
  16. Ann Surg. 1991 Aug;214(2):141-8 - PubMed
  17. Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1697-702 - PubMed
  18. Pituitary. 2007;10(2):189-203 - PubMed
  19. Br J Pharmacol. 2002 Aug;136(8):1146-52 - PubMed
  20. Eur J Pharmacol. 2003 Jul 25;473(2-3):171-6 - PubMed
  21. Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1483-7 - PubMed
  22. Neurosci Lett. 2003 May 29;343(1):25-8 - PubMed
  23. Arch Surg. 1997 Apr;132(4):364-9; discussion 369-70 - PubMed
  24. J Endocrinol Invest. 2000 Sep;23(8):493-5 - PubMed
  25. Mol Med. 2009 Nov-Dec;15(11-12):407-14 - PubMed
  26. Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1296-302 - PubMed
  27. Jpn J Physiol. 2003 Dec;53(6):443-9 - PubMed
  28. Gastroenterology. 2002 Oct;123(4):1120-8 - PubMed
  29. J Neurochem. 1996 Apr;66(4):1565-73 - PubMed
  30. J Immunol. 2002 Nov 1;169(9):4697-701 - PubMed
  31. Nature. 2002 Dec 19-26;420(6917):853-9 - PubMed
  32. Am J Respir Crit Care Med. 2003 Jul 15;168(2):165-72 - PubMed
  33. Shock. 1995 Jan;3(1):21-6 - PubMed
  34. Arch Surg. 1991 Feb;126(2):219-24 - PubMed
  35. J Surg Res. 1999 May 15;83(2):151-7 - PubMed
  36. Am J Physiol. 1995 Apr;268(4 Pt 1):G641-9 - PubMed
  37. Nature. 2003 Jan 23;421(6921):384-8 - PubMed
  38. Nature. 2000 May 25;405(6785):458-62 - PubMed
  39. Circulation. 2004 May 11;109(18):2221-6 - PubMed

Publication Types

Grant support